Ultra-rapid brain uptake of subcutaneous sumatriptan in the rat: Implication for cluster headache treatment. (April 2020)

• Record Type: Journal Article
• Authors: Muzzi, Mirko; Zecchi, Riccardo; Ranieri, Giuseppe; Urru, Matteo; Tofani, Lorenzo; De Cesaris, Francesco; Panconesi, Alessandro; Chiarugi, Alberto
• Is Part Of: Cephalalgia. Volume 40:Number 4(2020)
• Page Start: 330
• Page End: 336
• Publication Date: 2020-04
• Subjects: Triptans -- pharmacokinetics -- migraine; Headache -- Periodicals; 616.8491
• DOI: 10.1177/0333102419896370
• Languages: English
• ISSNs: 0333-1024

Abstract

Background: In spite of the substantial therapeutic efficacy of triptans, their site of action is still debated. Subcutaneous sumatriptan is the most efficacious symptomatic treatment for cluster headache (CH) patients, showing therapeutic onset within a few minutes after injection even in migraine patients. However, whether subcutaneous sumatriptan is able to reach the CNS within this short time frame is currently unknown. Methods: Here, by means of liquid chromatography/mass spectrometry, we investigated peripheral and brain distribution of subcutaneous sumatriptan soon after injection in rats at a dose equivalent to that used in patients. Tissue sumatriptan contents were compared to those of oxazepam, a prototypical lipophilic, neuroactive drug. Results: We report that sumatriptan accumulated within brain regions of relevance to migraine and CH pathogenesis such as the hypothalamus and the brainstem as soon as 1 and 5 minutes after injection. Notably, sumatriptan brain distribution was faster than that of oxazepam, reaching concentrations exceeding its reported binding affinity for 5HT1B/D receptors, and in the range of those able to inhibit neurotransmitter release in vivo . Conclusion: Our findings indicate that sumatriptan distributes within the CNS soon after injection, and are in line with prompt pain relief by parenteral sumatriptan in CH patients.